[1] |
Ullah R, Yin Q, Snell AH, et al. RAF-MEK-ERK pathway in cancer evolution and treatment[J]. Semin Cancer Biol, 2022, 85: 123-154.
doi: 10.1016/j.semcancer.2021.05.010
|
[2] |
Hussain MR, Baig M, Mohamoud HS, et al. BRAF gene: from human cancers to developmental syndromes[J]. Saudi J Biol Sci, 2015, 22(4): 359-373.
doi: 10.1016/j.sjbs.2014.10.002
|
[3] |
Dard L, Bellance N, Lacombe D, et al. RAS signalling in energy metabolism and rare human diseases[J]. Biochim Biophys Acta Bioenerg, 2018, 1859(9): 845-867.
doi: 10.1016/j.bbabio.2018.05.003
|
[4] |
Meng P, Bedolla RG, Yun H, et al. Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness[J]. Mol Carcinog, 2019, 58(9): 1701-1710.
doi: 10.1002/mc.v58.9
|
[5] |
Cao H, Alrejaye N, Klein OD, et al. A review of craniofacial and dental findings of the RASopathies[J]. Orthod Craniofac Res, 2017, 20 (Suppl 1): 32-38.
doi: 10.1111/ocr.2017.20.issue-S1
|
[6] |
Poulikakos PI, Sullivan RJ, Yaeger R, et al. Molecular pathways and mechanisms of BRAF in cancer therapy[J]. Clin Cancer Res, 2022, 28(21): 4618-4628.
doi: 10.1158/1078-0432.CCR-21-2138
pmid: 35486097
|
[7] |
Hebron KE, Hernandez ER, Yohe ME, et al. The RASopathies: from pathogenetics to therapeutics[J]. Dis Model Mech, 2022, 15(2): dmm049107.
doi: 10.1242/dmm.049107
|
[8] |
Rauen KA. The RASopathies[J]. Annu Rev Genom Hum G, 2013, 14(1): 355-369.
doi: 10.1146/genom.2013.14.issue-1
|
[9] |
Suzuki-Muromoto S, Miyabayashi T, Nagai K, et al. Leucine-485 deletion variant of BARF may exhibit the severe end of the clinical spectrum of CFC syndrome[J]. J Hum Genet, 2019, 64(5): 499-504.
doi: 10.1038/s10038-019-0579-3
pmid: 30842599
|
[10] |
Pierpont ME, Magoulas PL, Adi S, et al. Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines[J]. Pediatrics, 2014, 134(4): e1149-e1162.
|
[11] |
陈柏谕, 尹飞, 陈施梦, 等. BRAF基因突变所致心-面-皮肤综合征1例并文献复习[J]. 中南大学学报(医学版), 2021, 46(4): 432-437.
|
[12] |
Jhang WK, Choi JH, Lee BH, et al. Cardiac manifestations and associations with gene mutations in patients diagnosed with RASopathies[J]. Pediatr Cardiol, 2016, 37(8): 1539-1547.
pmid: 27554254
|
[13] |
Pierpont EI, Kenney-Jung DL, Shanley R, et al. Neurologic and neurodevelopmental complications in cardiofaciocutaneous syndrome are associated with genotype: a multinational cohort study[J]. Genet Med, 2022, 24(7): 1556-1566.
doi: 10.1016/j.gim.2022.04.004
pmid: 35524774
|
[14] |
Zenker M, Edouard T, Blair JC, et al. Noonan syndrome: improving recognition and diagnosis[J]. Arch Dis Child, 2022, 107(12): 1073-1078.
doi: 10.1136/archdischild-2021-322858
pmid: 35246453
|
[15] |
Feng S, Han L, Yue M, et al. Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing[J]. Orphanet J Rare Dis, 2021, 16(1): 272.
doi: 10.1186/s13023-021-01912-3
|